Hereditary Angioedema Treatments to Get New Data Review
Patients with this condition will see new safety and usage research presented at an upcoming medical meeting in Phoenix.
Updated on Oct. 29, 2026 in Allergies
Live Poll
Do you believe clinical study updates from pharmaceutical companies help you better manage your own health?
BioCryst Pharmaceuticals will present four new research abstracts on treatments for hereditary angioedema at the American College of Allergy, Asthma and Immunology annual meeting. These findings, which include data on long-term safety and healthcare utilization, will be shared at the Phoenix Convention Center from November 12-16, 2026.
Why it matters
Understanding real-world outcomes and safety profiles for hereditary angioedema therapies is critical for patients managing this rare condition. The upcoming presentation aims to update the clinical understanding of existing oral treatments and new investigative therapies.
The upcoming presentations consist of four research abstracts evaluating clinical data, including long-term safety and healthcare utilization metrics, for hereditary angioedema treatments. The specific outcomes of these studies remain subject to the full data disclosure at the meeting.
The players
BioCryst Pharmaceuticals
A biotechnology company focused on developing oral and systemic therapies for rare diseases like hereditary angioedema.
American College of Allergy, Asthma and Immunology
A professional medical association that hosts annual scientific meetings to share advancements in allergy and immunology research.
The details
The research focuses on the clinical profile of ORLADEYO, an oral therapy for patients aged two and older, and Navenibart, an injectable monoclonal antibody inhibitor. Posters will address dose adjustments and potential dosing intervals for Navenibart, which is currently under investigation for administration every three or six months. The abstracts further evaluate how these therapies influence hospitalization frequency and broader healthcare resource use in the hereditary angioedema patient population.
Timeline
November 12-16, 2026: ACAAI 2026 Annual Scientific Meeting occurs in Phoenix.
November 13, 2026: Poster R077 presentation at 4:20-4:35 p.m. MT.
November 14, 2026: Posters R096 and R097 presentations.
November 15, 2026: Poster R110 presentation at 12:00-12:15 p.m. MT.
Health Landscape
The upcoming presentations at the American College of Allergy, Asthma and Immunology Annual Scientific Meeting reflect a broader industry effort to optimize long-term management strategies for hereditary angioedema. This research helps clarify the practical role of oral therapies and long-acting injectable inhibitors in reducing patient hospitalizations.
Patients and caregivers currently managing hereditary angioedema should monitor these updates to understand potential changes in treatment safety and efficacy profiles. It is worth discussing any emerging data on long-term outcomes with your specialist to ensure your current care plan aligns with the latest research.
The takeaway
The research highlights ongoing improvements in managing hereditary angioedema through both oral and injectable options. Patients should keep a record of their symptom frequency and current treatment response to review with their physician during their next scheduled appointment.
Further reading
For more on the current standard of care and management strategies, visit Allergies.
More information
For detailed resources, visit the ORLADEYO patient and treatment information page.
Source note: This article includes information reported by The Manila times.
Live Poll
Do you believe clinical study updates from pharmaceutical companies help you better manage your own health?
